Lijuan Fang

机构：Peking University, Beijing Jishuitan Hospital, Center for Tuberculosis Control of Guangdong Province, Hohhot First Hospital, Wuhan YZY Biopharma (China) · ORCID：0000-0002-5765-0210

发表论文 73 篇 · 总被引 1239 次 · h-index 16

代表论文

• CRISPR-cas technology: A key approach for SARS-CoV-2 detection (2023 · Frontiers in Bioengineering and Biotechnology · 被引 36)
• Association between lipoprotein(a), fibrinogen and their combination with all-cause, cardiovascular disease and cancer-related mortality: findings from the NHANES (2024 · BMC Public Health · 被引 16)
• Synergistic effect of lipoprotein(a) and high-sensitivity C-reactive protein on the risk of all-cause and cardiovascular death in patients with acute myocardial infarction: a large prospective cohort study (2024 · Frontiers in Endocrinology · 被引 11)
• Vitamin D deficiency linked to abnormal bone and lipid metabolism predicts high-risk multiple myeloma with poorer prognosis (2023 · Frontiers in Endocrinology · 被引 10)
• Persistent lipoprotein(a) exposure and its association with clinical outcomes after acute myocardial infarction: a longitudinal cohort study (2025 · Annals of Medicine · 被引 8)
• Performance comparison of two automated digital morphology analyzers for leukocyte differential in patients with malignant hematological diseases: Mindray MC ‐80 and Sysmex DI ‐60 (2024 · International Journal of Laboratory Hematology · 被引 8)